Literature DB >> 34625953

Continuous seizure emergency evoked in mice with pharmacological, electrographic, and pathological features distinct from status epilepticus.

Kevin M Knox1, Dannielle K Zierath1, H Steve White1, Melissa Barker-Haliski1.   

Abstract

OBJECTIVES: Benzodiazepines are the standard of care for the management of sustained seizure emergencies, including status epilepticus (SE) and seizure clusters. Seizure clusters are a variably defined seizure emergency wherein a patient has multiple seizures above a baseline rate, with intervening periods of recovery, distinguishing clusters from SE. Although these seizure emergencies are phenotypically distinct, the precise pathophysiological and mechanistic differences between SE and seizure clusters are understudied. Emergency-specific preclinical models may differentiate the behavioral and pathological mechanisms that are acutely associated with seizure emergencies and seizure termination to better manage these events.
METHODS: Herein we characterize a novel model of sustained seizure emergency induced in CF-1 mice through the combined administration of high-dose phenytoin (PHT; 50 mg/kg, i.p.) and pentylenetetrazol (PTZ; 100 mg/kg, s.c.).
RESULTS: We presently describe a mouse model of sustained seizure emergency that is pathologically, pharmacologically, and behaviorally distinct from SE. Acute administration of PHT 1 h prior to PTZ led to significantly more mice with unremitting continuous seizure activity (CSA; 73.4%) vs vehicle-pretreated mice (13.8%; p < .0001). CSA was sensitive to lorazepam and valproic acid when administered at seizure onset and 30 minutes later. Carbamazepine worsened seizure control and post-CSA survival. Mice in CSA exhibited electroencephalography (EEG) patterns distinct from kainic acid-induced SE and PTZ alone, clearly differentiating CSA from SE and PTZ-induced myoclonic seizures. Neuropathological assessment by Fluoro-Jade C staining of brains collected 24 h post-CSA revealed no neurodegeneration in any mouse that underwent CSA, whereas there was widespread neuronal death in brains from KA-SE mice. Finally, immunohistochemistry revealed acute seizure-induced astrogliosis (glial fibrillary acid protein; GFAP) in hippocampal structures, whereas hippocampal neuronal nuclei (NeuN) protein expression was only reduced in KA-SE mice. SIGNIFICANCE: We present a novel mouse model on which to further elucidate the mechanistic differences between sustained seizure emergencies (ie, SE and seizure clusters) to improve clinical interventions and define mechanisms of seizure termination.
© 2021 International League Against Epilepsy.

Entities:  

Keywords:  astrocytes; carbamazepine; continuous seizure activity; pentylenetetrazol; phenytoin

Mesh:

Substances:

Year:  2021        PMID: 34625953      PMCID: PMC8639616          DOI: 10.1111/epi.17089

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  55 in total

1.  Animal research: reporting in vivo experiments--the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  J Cereb Blood Flow Metab       Date:  2011-01-05       Impact factor: 6.200

2.  Refractory status epilepticus: frequency, risk factors, and impact on outcome.

Authors:  Stephan A Mayer; Jan Claassen; Johnny Lokin; Felicia Mendelsohn; Lyle J Dennis; Brian-Fred Fitzsimmons
Journal:  Arch Neurol       Date:  2002-02

3.  Seizure cluster: Definition, prevalence, consequences, and management.

Authors:  Saba Jafarpour; Lawrence J Hirsch; Marina Gaínza-Lein; Christoph Kellinghaus; Kamil Detyniecki
Journal:  Seizure       Date:  2018-05-21       Impact factor: 3.184

4.  A hospital-based study on caregiver preferences on acute seizure rescue medications in pediatric patients with epilepsy: Intranasal midazolam versus rectal diazepam.

Authors:  Sunjay Nunley; Peter Glynn; Steve Rust; Jorge Vidaurre; Dara V F Albert; Anup D Patel
Journal:  Epilepsy Behav       Date:  2019-01-03       Impact factor: 2.937

Review 5.  Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies.

Authors:  Wolfgang Löscher
Journal:  Epilepsy Res       Date:  2016-08-01       Impact factor: 3.045

6.  Development of spontaneous recurrent seizures after kainate-induced status epilepticus.

Authors:  Philip A Williams; Andrew M White; Suzanne Clark; Damien J Ferraro; Waldemar Swiercz; Kevin J Staley; F Edward Dudek
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

7.  Withdrawal of antiepileptic drugs during presurgical video-EEG monitoring: an observational study for evaluation of current practice at a referral center for epilepsy.

Authors:  O Henning; A Baftiu; S I Johannessen; C Johannessen Landmark
Journal:  Acta Neurol Scand       Date:  2013-08-28       Impact factor: 3.209

8.  Mouse strain differences in kainic acid sensitivity, seizure behavior, mortality, and hippocampal pathology.

Authors:  G M McKhann; H J Wenzel; C A Robbins; A A Sosunov; P A Schwartzkroin
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

9.  Diurnal burden of spontaneous seizures in early epileptogenesis in the post-kainic acid rat model of epilepsy.

Authors:  Stephanie Mizuno; Zachery Koneval; Dannielle K Zierath; Kevin M Knox; H Steve White; Melissa Barker-Haliski
Journal:  Epilepsia Open       Date:  2021-05-03

10.  Tackling obstacles for gene therapy targeting neurons: disrupting perineural nets with hyaluronidase improves transduction.

Authors:  Klaus Wanisch; Stjepana Kovac; Stephanie Schorge
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

View more
  1 in total

1.  Reductions in Hydrogen Sulfide and Changes in Mitochondrial Quality Control Proteins Are Evident in the Early Phases of the Corneally Kindled Mouse Model of Epilepsy.

Authors:  Christi Cho; Maxwell Zeigler; Stephanie Mizuno; Richard S Morrison; Rheem A Totah; Melissa Barker-Haliski
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.